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Accumulation of hyperphosphorylated Tau protein as paired
helical filaments in pyramidal neurons is a major hallmark of
Alzheimer disease. Besides hyperphosphorylation, other modi-
fications of the Tau protein, such as cross-linking, are likely to
contribute to the characteristic features of paired helical fila-
ments, including their insolubility and resistance against pro-
teolytic degradation. In this study, we have investigatedwhether
the four reactive carbonyl compounds acrolein, malondialde-
hyde, glyoxal, and methylglyoxal accelerate the formation of
Tau oligomers, thioflavin T-positive aggregates, and fibrils
using wild-type and seven pseudophosphorylated mutant Tau
proteins. Acrolein and methylglyoxal were the most reactive
compounds followed by glyoxal and malondialdehyde in terms
of formation of Tau dimers and higher molecular weight oli-
gomers. Furthermore, acrolein and methylglyoxal induced the
formation of thioflavin T-fluorescent aggregates in a triple
pseudophosphorylation-mimicking mutant to a slightly higher
degree than wild-type Tau. Analysis of the Tau aggregates by
electron microscopy study showed that formation of fibrils
using wild-type Tau and several Taumutants could be observed
with acrolein and methylglyoxal but not with glyoxal and
malondialdehyde. Our results suggest that reactive carbonyl
compounds, particularly methylglyoxal and acrolein, could
accelerate tangle formation in vivo and that this process
could be slightly accelerated, at least in the case of methylg-
lyoxal and acrolein, by hyperphosphorylation. Interference
with the formation or the reaction of these reactive carbonyl
compounds could be a promising way of inhibiting tangle
formation and neuronal dysfunction in Alzheimer disease
and other tauopathies.
Neurofibrillary tangles, composed of bundles of paired heli-
cal filaments (PHFs),3 consist of hyperphosphorylated and
aggregated forms of the microtubule-associated protein Tau.
Neurofibrillary tangles are major hallmarks of neurodegenera-
tive diseases including Alzheimer disease (AD) (1). Under non-
pathological conditions, Tau is a developmentally regulated
phosphoprotein that promotes assembly and stability ofmicro-
tubules and is thus involved in axonal transport (2, 3). In AD
and other tauopathies, Tau proteins aggregate and form fibril-
lar insoluble intracellular inclusions, so-called neurofibrillary
tangles. It has been suggested that ionic interactions and cova-
lent cross-linking contribute to pathological Tau aggregation
and tangle formation. For example, ionic interactions with glu-
cosaminoglucans (4–7),Mg2orCa2 (8), Al3 andFe2/Fe3
(9–12), or covalent modifications such as glycosylation (13,
14), glycation (15, 16), or the formation of disulfide bridges
(17) have been shown to favor the formation of Tau aggre-
gates in vitro.
More recently, reactive carbonyl compounds (RCCs), which
are increased under conditions of oxidative stress and in aging
(18, 19), have attracted interest as potential bifunctional com-
pounds responsible for promoting cross-linking between pro-
teins and favoring their aggregation. Protein modifications by
such RCCs, including the lipid peroxidation products 4-hy-
droxy-2-nonenal (20), malondialdehyde (MDA) (15, 21, 22),
and acrolein (2-propen-1-al) (23) have been detected immuno-
histochemically in AD brains, particularly in neurofibrillary
tangles. Advanced lipid peroxidation end products (ALEs) have
also been described to be increased in the cerebrospinal fluid of
AD patients (21, 24, 25). Glyoxal, a product of lipid peroxida-
tion or glycation, andmethylglyoxal (MG), formed by oxidation
of sugars or produced as an intermediate of triosephosphate,
threonine, and glycine catabolism, reacts with proteins to form
“advanced glycation end products” (AGEs). Immunohisto-
chemical analysis indicates that glyoxal/MG-derivedAGE anti-
bodies label predominantly PHF in aggregates (26–28).
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Hyperphosphorylation is a second important modification,
which has been suggested to contribute to Tau aggregation.
Tau can be phosphorylated at 30 sites; however, little is
known about which phosphorylation sites actually enhance
Tau fibril formation. In in vitro aggregation assays, introduc-
tion of a negative charge by substitution of serine or threonine
by glutamic acid or aspartic acid residues (“pseudophosphoryl-
ation”) has been shown to mimic the effect of phosphorylation
of Tau (29). Such Tau mutants have been used to examine the
influence of phosphorylation at distinct sites on Tau aggrega-
tion induced by heparin and certain metal ions. It has been
shown that these “pseudophosphorylated” Tau mutants, par-
ticularly those carrying substitutions in C-terminal regions,
have a slightly higher tendency to aggregate than the Tau wild-
type protein (30).
In this study, we wanted to elucidate whether the reactive
carbonyl compounds acrolein, glyoxal,MG, orMDAare able to
induce or accelerate Tau oligomerization, formation of thiofla-
vin T-positive Tau aggregates, and formation of PHFs. Further-
more, we wanted to investigate whether this aggregation proc-
ess is accelerated by phosphorylation at specific sites using
eight different pseudophosphorylated Tau mutants.
MATERIALS ANDMETHODS
Construction of Expression Plasmids for Tau Mutants and
Purification of Recombinant Proteins—Constructs for the Tau
mutants were prepared as described previously (30). Briefly,
codons for the amino acids representing the potential phospho-
rylation sites (Thr or Ser) were changed to GAA (glutamate) or
GAT (aspartate) using one-tube, two-stage, PCR-directed in
vitromutagenesis. Mutant blunt-ended constructs were cloned
into the EcoRV site of pZerO-2 and verified by DNA sequenc-
ing. For protein expression, Tau constructs were cloned into
the EcoRI/NotI sites of pGEX-6P-1 and expressed as glutathi-
one S-transferase fusion proteins. pGEX-6P-1 plasmids were
transformed into Escherichia coli (BL21-CodonPlus(DE3)-RIL)
cells. Cells were grown in LB medium supplemented with 50
g/ml ampicillin and 50 g/ml chloramphenicol overnight.
Cells were grown to late exponential phase (A600 1.5) and
induced with 1 mM isopropyl--thiogalactosidase for 2 h at
30 °C. The cell suspension was centrifuged at 7000 g for 10
min at 4 °C and the cell pellet resuspended in 1⁄20 of the volume
of 1 binding buffer (140 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 1.8mMKH2PO4, pH7.3). Cells were then lysed using
a sonicator. To facilitate solubilization of protein, 1% (v/v) Tri-
ton X-100, lysozyme (4000 units/ml), and benzonase (4 units/
ml) were added, and the mixture slowly shaken for 1 h at 4 °C.
The clarified lysate was incubated with glutathione-Sepharose
4B for 2 h to bind the expressed fusion proteins. After washing
thematrix two times with binding buffer, the recombinant pro-
tein was eluted by site-specific proteolysis using PreScissionTM
protease (10 units/ml) overnight at 4 °C. Protein concentration
was quantified according to the method of Bradford (31).
Modification of Tau with Reactive Carbonyl Compounds—
Glyoxal (trimer dihydrate) and acrolein (Sigma) were used
without further purification.Methylglyoxalwas freshly distilled
from a 40% solution and then stored at 80 °C before use. Its
concentration was determined according to a method
described previously (32). Malondialdehyde was generated in
situ from malondialdehyde bis(dimethyl)acetate by hydrolysis
with 1 mM HCl for 5 min. Tau protein (3 mg/ml) was dissolved
in 20 mM MOPS (pH 7.0) and incubated with each of the car-
bonyl compounds (in the concentrations indicated) in a
microvessel at 37 °C for up to 96 h.
Determination of TauModification andAggregate Formation
by Gel Electrophoresis and Western Blot—Tau samples were
boiled for 5 min in Laemmli SDS sample buffer and separated
by SDS-PAGE on a 5–20% gradient polyacrylamide gel. The gel
was stained with Coomassie Brilliant Blue or forWestern blots;
Tau samples were transferred to nitrocellulose membrane.
Blots were blocked in Roti-Block (ROTH, Karlsruhe, Germany)
for 1 h at room temperature. Two different AGE antibodies
(6D12 and 4G9)were used. The 6D12 antibody (1:1000) (Trans-
Genic, Inc., Kumamoto, Japan) is an antibody with broad spec-
ificity. It has been described to detect AGE-human serum albu-
min/bovine serum albumin, AGE--Tos-Lys, AGE--Tos-Lys-
o-Me, AGE--alanine, AGE--aminobutyric acid, AGE--
amino capronic acid. But no Schiff bases, Amadori products,
unmodified human serum albumin/bovine serum albumin,
poly(Lys), unmodified Lys-derivatives, unmodified mono-
amino-carbonic acids, FFI, pyrrolaldehyde, and pentosidin)
(33, 34) The carboxymethyllysine (CML) antibody 4G9,
(1:1000) (Roche Diagnostics) predominantly detects CML res-
idues. Membranes were incubated with the antibodies for 16 h
at 4 °C. After five washing steps with TBST (Tris-buffered
saline containing 0.1% Tween 20 and thioflavin T (ThT)), a
horseradish peroxidase rabbit anti-mouse antibody (Dako,
Hamburg, Germany, 1:1500) was applied for 1 h at room tem-
perature. After five washing steps with TBST, the blots were
developed on hyperfilms using the ECL kit (Amersham Bio-
sciences AB, Uppsala, Sweden).
Determination of Tau Aggregate Formation by Thioflavin T
Assay—Tau (S396D/T403E/S404D) or wild-type Tau (each 1.7
mg/ml) was dissolved in 20 mM MOPS (pH 7.0). Thioflavin T
was added (final concentration of 5 M) and either incubated
without or with 1 mM methylglyoxal or acrolein at 37 °C for
72 h. Thioflavin T fluorescence was analyzed in a volume of 100
l in a 96-well plate (excitation, 400 nm; emission, 485 nm).
Fluorescence values were set as 100% for proteins containing
ThT, and changes were recorded after the addition of RCCs. As
negative controls, buffer samples containing thioflavin T and
either acrolein or methylglyoxal were used.
Determination of Tau Aggregate Formation by Electron
Microscopy—Filament formation was analyzed by electron
microscopy. Samples were placed on a nickel slot grid and
stained with 2% uranyl acetate for 1 min. The grids were
examined in a 912 OMEGA electronmicroscope (Zeiss, Ger-
many) equipped with a digital camera (charge-coupled
device-slow scan, Proscan). All images were performed at a
magnification of 80,000 and processed in Adobe Photo-
shop (scale bars  100 nm) (Fig. 6).
RESULTS
Formation of Tau Multimers by Reactive Carbonyl Com-
pounds; Detection by SDS-PAGE and Commassie Blue Stain—
Recombinant humanTau (full-length ofwild-typeTau) and the
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following six Tau mutants with the following phospho-
rylation-mimicking amino acid substitutions were used: (a)
(single substitution) aspartic acid replacing threonine at posi-
tion 217 (T217D), aspartic acid replacing serine at position 262
(S262D), and glutamic acid replacing serine at position 422
(S422E); (b) (double substitution) glutamic acid replacing thre-
onine both at positions 111 and 153 (T111E/T153E), aspartic
acid replacing threonine at position 231, glutamic acid replac-
ing serine at position 235 (T231D/S235E), glutamic acid replac-
ing threonine at position 403, and aspartic acid replacing serine
at position 404 (T403E/S404D); (c) (triple substitution) aspartic
acid replacing serine at positions 396 and 404 and glutamic acid
replacing threonine at position 403 (S396D/T403E/S404D)
(Fig. 1). For the in vitro aggregation assays, the eight recombi-
nant Tau proteins were incubated with methylglyoxal, glyoxal,
acrolein, or malondialdehyde (Fig. 2), respectively, and then
separated on a reducing SDS-polyacrylamide gel and stained
with Commassie Blue.
In the first set of experiments, RCCs were used at a concen-
tration of 10mM. Because Tau protein, which contains 40 lysine
and 18 arginine residues, was used at a concentration of 3
mg/ml, 10 mM RCCs accord to a 2.5-fold excess/reactive basic
amino acid, allowing Tau to become
“maximally modified” (Table 1).
Reaction with Acrolein—All Tau
isoforms were completely con-
verted to high molecular weight
aggregates by 10 mM acrolein after
96 h (Fig. 3A). In some cases, diffuse
bands between 120 and 200 kDa
could be detected, whichmight rep-
resent highly modified dimers or
trimers. Interestingly, the appear-
ance of such multiple, diffuse Tau
protein multimers after polyacrylamide gel electrophoresis has
been reported previously for PHFs isolated fromADbrains (35,
36). In some cases, e.g. in the Tau T403E/S404D mutant, the
combined intensity of all bands appears to be far lower than
with the other RCCs. Possible explanations for this apparent
loss of total Tau protein might be the formation of high molec-
ular weight Tau multimers too large to enter the gel or the low
affinity of Coomassie Blue to proteins having lost their positive
charges.
Reaction with Glyoxal—Incubation of wild-type Tau, Tau
T111E/T153E, Tau T217D, and Tau S422E with 10 mM glyoxal
resulted in a weakly stained band at 100–120 kDa (Fig. 3A),
which may suggest dimerization of these Tau isoforms. In con-
trast, the incubation of all other Tau mutants with glyoxal only
caused a small increase of the molecular weight of the mono-
mer but did not lead to the formation of dimeric or higher
oligomeric structures. The triple Tau mutant S396D/T403E/
S404D behaved quite unusually, because it produced a high
molecular oligomer, whereas the monomeric band at50 kDa
nearly disappeared.
Reaction with Malondialdehyde—When Tau proteins were
incubated with 10 mMMDA, formation of dimers (and trimers
in the case of T111E/T153E) could be observed at 100-
120 kDa after 96 h (Fig. 3A). Again, the Tau mutant S396D/
T403E/S404D behaved quite unusually, because it produced a
higher molecular oligomer, whereas the monomeric band at
50 kDa disappeared (Fig. 3A).
Reaction with Methylglyoxal—All seven pseudophosphoryl-
ated Taumutant proteins appeared to have reacted with 10mM
methylglyoxal after 96 h. Bands corresponding to a trimer (150
kDa), a tetramer (200 kDa), and higher molecular weight oligo-
meric Tau products 250 kDa could be observed (Fig. 3A).
With wild-type Tau, only a faint band at 120 kDa could be
observed.
Control Incubations without Reactive Carbonyl Compounds—
When wild-type Tau or the phosphorylation mimicking Tau
mutant proteins were incubated at 37 °C without carbonyl
compounds, no Tau dimers, oligomers, or other multimers
could be observed. These negative controls aremarkedwith c in
Fig. 3.
Because the results obtained from the experiments above
suggested that the reactivity of the RCCs decreased in this
order, acroleinmethylglyoxal glyoxalmalondialdehyde,
only themost reactive compounds, methylglyoxal and acrolein,
were used at lower, more physiological concentrations. At con-
centrations of 1mMRCCs, only each fourth at 250M and each
FIGURE 1.Constructs used for the expressionof pseudophosphorylated Taumutants. Phosphorylation of
Tau at specific sites was simulated by substituting serine or threonine with glutamic or aspartic acids, respec-
tively. Seven pseudophosphorylated mutants were created, the single mutant T217D (in which threonine in
position 219was replaced aspartic acid), S422E and S262D, the doublemutants T111E T153E, T231D/S235E,
and T403E/S404, and the triple mutant S396D/T403E/S404D. One more construct used in this study was the
one forwild-type Tau (also termedwtt) containing the original sequencewithout any amino acid replacement.
FIGURE 2. Chemical structures of reactive carbonyl compounds and
routes to their formation. Non-enzymatic degradation of glucose or Ama-
dori products or glucose metabolism yields methylglyoxal or glyoxal, which
can react with proteins to form advanced glycation end products (AGEs).
Radical-induced lipid peroxidation yields reactive carbonyl compounds such
as acrolein, malondialdehyde, or glyoxal, which react with proteins to form
advanced lipid peroxidation end products (ALEs).
TABLE 1
Calculation of stoichiometric ratios between lysine and arginine
residues of human Tau proteins and different concentrations of RCCs
10 mM RCC represents an excess, which should yield maximally modified Tau
proteins.
Tau protein Reactive side chain
3 mg/ml 0.071 mM /10 mM RCC /1 mM RCC /250 M RCC
40 Lysine residues 2.8 mM 1/3.6 1/0.36 1/0.09
18 Arginine residues 1.3 mM 1/7.8 1/0.77 1/0.19
Reactive residues () 4.1 mM 1/2.5 1/0.25 1/0.06
Carbonyl-induced Tau Aggregation and Fibril Formation
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sixteenth lysine or arginine residue could be modified, respec-
tively (Tab. 1). As shown in Fig. 3B, the reaction of Tau with 1
mM acrolein or methylglyoxal also caused the disappearance of
Tau monomer and formation of high molecular weight oli-
gomers. In contrast, incubations with 250M acrolein ormeth-
ylglyoxal did not significantly convert Tau monomers into oli-
gomers within the 96 h period, although intensity of monomer
bands decreased and a significant increase in the apparent
molecular weight of Tau (2–3 kDa) could be observed (data not
shown). It was not possible to incubate theTau preparations for
longer timeperiods than 96h, because residual protease activity
led to obvious protein degradation. It has to be noted that some
of the non-modified Tau mutant protein preparations, e.g.
S262D and S396D/T403E/S404D already contained some
traces of oligomers (Fig. 3B, lanes c). These oligomers disap-
peared after incubation with 10 mM acrolein or methylglyoxal
but not with 1 mM (Fig. 3) or 250 M (data not shown).
AGE and ALE Modification of Tau Oligomers by Reactive
Carbonyl Compounds; Detection by SDS-PAGE and Western
Blot—Proteins modified with RCCs eventually form stable end
products, which are termed “advanced glycation” or “advanced
lipid peroxidation” end products (AGEs or ALEs). To investi-
gate whether higher molecular weight bands of Tau are AGE-
or ALE-modified, Western blot analysis was performed with
wild-type Tau after incubation with 10 mM acrolein, glyoxal,
methylglyoxal, and MDA for 96 h (samples were identical to
those shown in Fig. 3A). Glyoxal-, MDA-, and methylglyoxal-
modified Tau were strongly recognized by the AGE antibody
6D12, whereas acrolein-modified Tau was only weakly recog-
nized (Fig. 4, left panel). The specific CML antibody 4G9
detected glyoxal-modified Tau only (Fig. 4) but none of the
other carbonyl modifications (data not shown). As expected,
non-modified Tau showed no immunoreaction with the AGE
antibody (Fig. 4, lane c) or the CML antibody (data not shown).
These results suggest that most of the Tau oligomers are either
AGE- or ALE-modified, assuming that the monoclonal AGE
antibody not only detects AGEs but also some chemically sim-
ilar ALEs. However, it appears that the epitope formed by acro-
lein is quite unique and cannot be detected by a “conventional”
AGE antibody (37).
Formation of Tau Aggregates by Reactive Carbonyl Com-
pounds; Detection by Thioflavin T Fluorescence—Thioflavin T
is a fluorescent dye known to interact with fibrillar protein
aggregates such as Tau in neurofibrillary tangles. To study the
influence of RCCs and pseudophosphorylation on the forma-
tion of such aggregates, fibrils were detected by thioflavin T
after incubation with 1 mM RCCs for 96 h. The formation of
thioflavin T-positive aggregates in the mutants, except the tri-
FIGURE 3. A, Tau molecular weight changes and formation of Tau oligomers
with differing reactive carbonyl compounds. Recombinant Tau proteins
(wild-type and pseudophosphorylation mutants) were incubated each with
10mM acrolein (Acr), glyoxal (GO), MDA, orMG at 37 °C for 96 h. Proteinswere
separated by SDS-PAGE and stainedwith Coomassie Blue. Wild-type Tau and
TauT111E/T153E incubatedwithout any carbonyl servedas the controls (lane
c), whereas the other controls are shown in B. B, to evaluate the cross-linking
reactivity of the most reactive carbonyl compounds, acrolein and methylg-
lyoxal, at lower concentrations, and recombinant Tau proteins were incu-
bated with 1 mM acrolein and 1 mM MG. All Tau proteins incubated without
RCCs served as controls (lane c).
FIGURE 4. AGE/ALE modification of carbonyl-modified wild-type Tau.
Shown is a Western blot of wild-type Tau incubated without any carbonyl
(lane c), with acrolein (Acr), glyoxal (GO),MDA, andMG, each 10mM, for 96 h at
37 °C. Tau modifications were immunostained by the anti-AGE antibody
(clone 6D12), indicating that all carbonyls modify Tau to yield AGEs or ALEs,
respectively (left panel). Glyoxalmodificationof Tau couldbedetectedasCML
by use of the monoclonal 4G9 antibody (right panel).
Carbonyl-induced Tau Aggregation and Fibril Formation
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ple mutant S396D/T403E/S404D was not significantly
increased compared with wild-type Tau controls (data not
shown). In a further experiment investigating the time course of
thioflavin T-positive fibril formation, wild-type Tau and the
triple mutant were incubated with 1 mM acrolein or methylg-
lyoxal in the presence of 5 M thioflavin T for up to 72 h. The
Tau mutant S396D/T403E/S404D (but not wild-type Tau)
showed a slightly accelerated formation of thioflavin T-positive
aggregates when reacted with acrolein, which became signifi-
cant after 24 h (Fig. 5A). By contrast, methylglyoxal-induced
formation of thioflavinT-positive aggregates initially decreased
within the first 8 h of the reaction but continuously increased
thereafter in both wild-type Tau and in the triple mutant, with
the initial difference in favor of the mutant leveling out after
72 h (Fig. 5B). These data suggest that 1 mMmethylglyoxal and
acrolein generally enhances formation of thioflavin T-fluores-
cent aggregates (with the exception of wild-type
Tau acrolein) and that ThT-sensitive aggregate formation is
slightly favored at certain time points in the triple mutant (30).
Formation of Tau Aggregates by Reactive Carbonyl Com-
pounds; Detection by Electron Microscopy—Further investiga-
tions by electron microscopy were performed at this stage to
determine whether the reactive carbonyl compounds contrib-
ute to the formation of helical structures resembling the char-
acteristic PHFs in Alzheimer disease brains. A further reason
for such an experimentwas a previous report that such filamen-
tous structures are formed from glucose-modified (glycated)
recombinant Tau (35, 38). Analogous to the experiments
described above, wild-type Tau and the phosphorylation-mim-
icking Tau isoforms were incubated with different concentra-
tions of each carbonyl compound for 96 h. In a first set of
experiments, wild-type Tau and three pseudophosphorylation-
mimicking mutants T217D, T403E/S404D, and S422E were
maximally modified by 10 mM acrolein, glyoxal, MDA, and
methylglyoxal and studied by electron microscopy using nega-
tive staining.
Reaction with Acrolein—Tau incubated with 10 mM acrolein
formed PHF-like filaments with lengths of100 nm with both
wild-type Tau and all seven phosphorylation-mimicking Tau
isoforms. Fig. 6A exemplarily shows the filaments of wild-type
Tau, Tau T217D, T403E/S404D, and S422E. The formation of
these large fibrillar aggregates further indicates the high reac-
tivity of acrolein. This may also explain why almost no defined
small oligomers could be detected in the SDS gel after Coomas-
sie Blue staining.
Reaction with Glyoxal—Tau incubated with 10 mM glyoxal
did not form large fibrillar aggregates within 96 h. However,
small protofibrils could be detected with wild-type Tau, and
some amorphous structures were detected with the Tau
mutant T217D (data not shown).
Reaction with Malondialdehyde—Similarly, the incubation
of 10 mMMDAwith wild-type Tau did not yield fibrillar aggre-
gates, but rather amorphous structures were formed (data not
shown). The phosphorylation-mimicking mutants T217D and
T403E/S404D yielded only partially ordered rudimental fila-
mentous structures after MDA treatment, but did not show
distinctive PHF-like aggregates (data not shown).
Reaction with Methylglyoxal—Methylglyoxal also induced
the formation of PHF-like filaments, both in wild-type Tau and
in all phosphorylation-mimicking mutants (selected examples
are shown in Fig. 6B). As summarized in Table 2, 10 mM acro-
lein and methylglyoxal (but not glyoxal or MDA) induced the
formation of Tau oligomers larger than dimers and PHF-like
aggregates within the 96-h reaction period.
Control Incubations without Reactive Carbonyl Compounds—
All untreated Tau proteins yielded either diffuse or amor-
phous structures in electron microscopy under the same
experimental conditions. Exemplarily, controls for Tau
S262D and S396D/T403E/S404D are shown in Fig. 6C.
Formation of fibrils by electron microscopy was investigated
with themost reactive compounds, acrolein andmethylglyoxal,
also at lower concentrations. Using 1 mM acrolein or methylg-
lyoxal, only Tau S262D formed distinct filamentous structures
(Fig. 6C), maybe because it already contained a small amount of
oligomers in the control material (see Fig. 3B). All other Tau
mutants, with the exception of T404E/S404D, yielded small
protofibrils that could represent nascent filaments. As an
example, Tau S396D/T403E/S404Dmodified by 1 mM acrolein
or MG is shown in Fig. 6C. In contrast, Tau mutants not incu-
bated with RCCs yielded only diffuse structures (see Fig. 6C for
Tau S262D and S396D/T403E/S404D).
In summary, when Fig. 6, panel C is compared with panels A
and B, it is obvious that increasing carbonyl concentrations
increase the degree of filament formation. Furthermore, when
Tau proteins were incubated with any carbonyl at 250 M for
FIGURE 5.Determination of fibrillar Tau aggregates by ThT fluorescence
using wild-type Tau and Tau S396D/T403E/S404D. Tau proteins were
incubated with 1 mM acrolein (A) or 1 mM methylglyoxal (B), respectively, in
the presence of ThT at 37 °C for up to 72 h. Fluorescence of Tau samples
without the addition of RCCs was set as 100%. Data are expressed as
mean	 S.D. (n 2). * indicates significance (p
 0.05, Student’s t test).
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similar time periods, no filamentous structures could be
observed (data not shown).
DISCUSSION
Neurofibrillary tangles are major hallmarks of a variety of
neurodegenerative diseases, and elucidation of themechanisms
of their formation may provide targets for future therapies.
Two main post-translational modifications, which have been
found in neurofibrillary tangles, hyperphosphorylation and
AGEs and ALEs, may provide clues to unravel this mechanism.
Nearly a decade ago, it was suggested that carbonyl-derived
post-translational modifications of neurofilaments may
account for the biochemical properties of neurofibrillary tan-
gles, possibly as a result of extensive cross-links (22, 39).
Because of their relatively long half-life, cytoskeletal proteins
are preferred reactants with reactive carbonyl compounds,
such as lipid peroxidation products or glucose (40, 41). A first
attempt to induce Tau glycation in vitro was made by short
term incubation with glucose, but this did not result in the
formation of PHFs (42). However, glucose is one of the least
reactive physiologically relevant carbonyl compounds, and it
was not determined in that study (42) to what extent Tau was
actually modified by glucose or its degradation products. It also
remains an open question whether Amadori products or cross-
linking-active AGEs were formed during this short term incu-
bation. By using more reactive carbonyl compounds than glu-
cose in our experiments, we could induce formation of
AGE/ALE-modified Tau oligomers and, with acrolein and
methylglyoxal, PHF-like structures, which indicated that inten-
sive cross-linking by AGEs or ALEs favor formation of PHFs.
The reactivity of the four RCCs tested decreased in the fol-
lowing order: acroleinmethylglyoxal glyoxalmalondi-
aldehyde. Interestingly, only acrolein and methylglyoxal, the
two most reactive RCCs, formed PHFs in a concentration-de-
pendent manner. However, it is possible that MDA and glyoxal
would have also formed oligomers and PHF-like filaments if the
reaction had proceeded for amuch longer time period. It can be
assumed that the reaction of 10 mM acrolein or methylglyoxal
with Tau was nearly complete, which could explain the high
content of large PHF-like structures that were detected by elec-
tron microscopy. When 1 mM acrolein or methylglyoxal were
used, more protofibrils and less PHF-like structures were
observed. In contrast, the conversion of Tau proteins with 10
mMMDA and glyoxal within 96 h could have been incomplete,
and this may be the cause of why only a few small filamentous
FIGURE 6. Electron microscopy pictures of acrolein- and methylglyoxal-
modified Tau. Wild-type Tau, Tau T217D, T403E, or S422E were incubated
with 10 mM acrolein (A) or 10 mM methylglyoxal (B). Tau S262D and
S396D/T403E/S404Dwere reactedwith 1mMacrolein or 1mMmethylglyoxal,
respectively, or without RCCs (C). All reactions were performed for 96 h at
37 °C. Scale bars represent a distance of 100 nm.
TABLE 2
Summary of Tau aggregate types upon incubation with 10 mM RCCs,
analyzed by SDS-PAGE and EM
Monomer Dimers Oligomers (largeraggregates)
Microscopic
fibrils
No RCC    
Acrolein    
Methylglyoxal    
Glyoxal    
MDA    
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structures (protofibrils) could be observed. Such an incomplete
reactionmay explain why no PHF-like filaments were observed
when Tau was incubated with glucose (42). Acrolein immuno-
reactivity has been observed in more than half of all paired
helical filaments (PHF)-1-labeled neurofibrillary tangles in AD
cases (23). Acrolein is known as the most reactive among the
,-unsaturated aldehyde products of lipid peroxidation (100
timesmore reactive than hydroxynonenal) and has been shown
to be increased in the amygdala and hippocampal/parahip-
pocampal gyrus of AD patients compared with normal controls
(18). The reaction of acrolein with nucleophilic amino acids of
Tau results in the formation of Michael adducts (43). A further
intramolecular reaction of the lysine adducts of acrolein was
described yielding N-(3-formyl-3,4-dehydropiperidino)lysine
(44). However, the exact structure of an acrolein-based protein
cross-link has not been published so far.
Glyoxal has been shown to form CML via an intramolecular
Cannizzaro reaction (45). In AD, CML is co-localized with Tau
in neurofibrillary tangles (46, 47). This explains the immunore-
activity of the CML antibody with Tau oligomers in the West-
ern blots. A cross-linking-active AGE formed by glyoxal (e.g.
present in the dimer at 100 kDa) could be the imidazolium
cross-linked glyoxal-lysine dimer GOLD (48).
In ADbrains,MDAhas only been described in deposits asso-
ciated with lipofuscin (21). However, increased levels of MDA
have been found in AD patients, particularly in their temporal
cortex (49). One of the reaction products of MDA with lysine
residues isN-(2-propenal)lysine (50). It is conceivable that this
residue subsequently reacts further withMDA and forms cova-
lent protein-protein cross-links, but to our knowledge such
defined cross-links have not yet been described.
The reaction of MG may result in the formation of N-(1-
carboxyethyl)lysine, hydroimidazolone, or argpyrimidine (51).
Thus far, specific antibodies for carboxymethyllysine and arg-
pyrimidine, major products in the reaction of methylglyoxal
with lysine or arginine, have not been used for immunohisto-
chemical analyses of AD brains. Dimers and oligomers can be
formed by anMG-derived C–C cross-link between lysine, argi-
nine, and cysteine residues (52) of Tau or by an imidazolium-
AGE cross-link, such as that found in the methylglyoxal-lysine
dimers MOLD and MODIC (53). Most of the Tau modifica-
tions or oligomers occurred as a double band. This may be due
to the fact that Tau polymers themselves can be modified on
their protein side chain. The Tau filaments, which were pro-
duced by the reaction with acrolein or methylglyoxal (Fig. 6)
show some resemblance to PHFs isolated from AD brains (1).
These AD filaments are530 nm long with characteristic sub-
units of 16 82 nm (54). However, our synthetic filaments
are similar but are straight and lack the twisted appearance of
the PHF isolated in vivo. In summary, our results obtained with
acrolein and methylglyoxal suggest that the formation of
covalently linked dimers, trimers, or tetramers may be an
important step in filament assembly (17, 55, 56). Consistent
with such a suggestion, a Tau tetramer was previously sug-
gested as the smallest building block of AD-derived PHFs when
PHF images were analyzed quantitatively from atomic force
microscopy and electron microscopy (54).
A further question addressed in this study was the influ-
ence of phosphorylation (mimicked by pseudophosphoryla-
ted mutants) on carbonyl-induced Tau oligomerization,
aggregation, and filament assembly. In terms of non-cova-
lent interactions, in vitro studies indicate that phosphoryla-
tion of Tau favors self-assembly and the formation of
paired helical filaments (57). Using pseudophosphorylated
mutants, phosphorylation was simulated by the replacement of
serine/threonine residueswithglutamicacidoraspartic acid in the
C-terminal portion (30). Such mutations mimic the negative
charge ofOPO3. Self-aggregation induced by heparin and cer-
tain metal ions, such as iron and aluminum, is also accelerated in
these mutants (30). We asked the question whether pseudophos-
phorylation influences the reaction with reactive carbonyl com-
pounds and the formation of Tau oligomers. Although the single
and double hyperpseudophosphorylated mutants did not signifi-
cantly form more thioflavin T-positive aggregates (data not
shown), the triple Tau mutant S396D/T403E/S404D reacts
slightly faster and formsmoreThTaggregates in the reactionwith
acrolein compared with wild-type Tau (Fig. 5A). Similarly, modi-
fication withmethylglyoxal also leads to a higher aggregation rate
in the triple mutant than in wild-type Tau, at least at some time
points (Fig. 5B). Taken together, our data confirm the hypothesis
that reactivecarbonylcompoundssuchasmethylglyoxal andacro-
lein induce dimerization, oligomerization, and the formation of
PHF-like aggregates and that this reactionmay bemodestly accel-
erated in triple pseudophosphorylated Tau compared with wild-
type Tau. In summary, our study did not point to particularly cru-
cial sites where phosphorylation would dramatically accelerate
Tau cross-linking and aggregation. It might be possible, however,
that the bulk effect of a larger number of (pseudo)phosphorylated
residues might lead to a dramatically increased susceptibility to
aldehyde-induced aggregation.
Furthermore, we have shown that the rate of PHF-like aggre-
gate formation increases with increasing carbonyl concentra-
tions. There are various reasons for the increased carbonyl con-
centration in the aging brain and in AD. Increased oxidative
stress and subsequent peroxidation would result in increased
levels of MDA and acrolein (58). In addition, impaired glucose
utilization or a decreased activity of triosephosphate isomerase
would increase triose phosphates and thus its degradation
product methylglyoxal (59). Moreover, a reduced activity of
detoxification systems such as aldose reductase or the glyox-
alase system and a low level of GSH, the co-factor of both
enzymes,may elevate the intra- and extracellular concentration
of RCCs (60). Because reduced glutathione is limited under
conditions of oxidative stress and inflammation, as is present in
AD, supplementation with antioxidants such as vitamin C and
E or flavonoids could indirectly strengthen the anti-glycation
defense system inAD. In addition, interference with the forma-
tion of cross-link-reactive AGEs or ALEs by scavenging RCCs
with drugs such as aminoguanidine or tenilsetam could become
a novel therapeutic approach to inhibit tangle formation and
slow down the progression of AD (61, 62).
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